Compare PCT & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | PCT | ANL |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Environmental Services | |
| Sector | Utilities | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 998.8M |
| IPO Year | 2020 | 2022 |
| Metric | PCT | ANL |
|---|---|---|
| Price | $2.95 | $10.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $10.60 | ★ $29.50 |
| AVG Volume (30 Days) | ★ 6.0M | 279.1K |
| Earning Date | 11-05-2026 | 08-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.86 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,355,000.00 | N/A |
| Revenue This Year | $269.48 | $243.83 |
| Revenue Next Year | $262.99 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.84 | $0.88 |
| 52 Week High | $14.20 | $17.25 |
| Indicator | PCT | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 16.04 | 36.19 |
| Support Level | N/A | $8.96 |
| Resistance Level | $6.23 | $12.49 |
| Average True Range (ATR) | 0.28 | 1.45 |
| MACD | -0.06 | -0.52 |
| Stochastic Oscillator | 4.02 | 14.27 |
PureCycle Technologies Inc is a Florida-based corporation focused on commercializing a patented dissolution process to physically separate the polymer from other plastics, color, and contaminants (the Technology), originally developed by The Procter & Gamble Company (P&G), for restoring waste polypropylene into resin with near-virgin characteristics, called PureFive resin. PureFive resin represents the family of recycled resin products produced, including ultra-pure resin and other grades used for compounding to meet customer specifications, which has similar properties and applicability for reuse as virgin polypropylene. It has a single operating segment, which encompasses integrated business activities related to the recycling of polypropylene into resins.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.